Successful Enrollment of Patients in VIRAGE Phase 2b Trial
Theriva™ Biologics, Inc. (NYSE American: TOVX), a clinical-stage company dedicated to advancing innovative cancer therapies, has reached a significant achievement: the successful enrollment of patients in their VIRAGE Phase 2b trial. The objective is to enroll 92 evaluable patients, split evenly between a control group and a treatment group. Theriva accomplished this milestone across 15 sites in the USA and Europe in just 21 months. This clinical trial aims to assess how effective VCN-01, paired with gemcitabine/nab-paclitaxel, works for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
What is VCN-01?
Central to this trial is VCN-01, an oncolytic adenovirus specifically engineered to target and eliminate cancer cells while also breaking down the surrounding dense tissue, known as stroma, which can impede treatment effectiveness. With both Orphan Drug and Fast Track Designations from the FDA, VCN-01 is positioned as a potentially groundbreaking therapy for a cancer type that currently offers limited treatment options.
Leadership Comments
Steven A. Shallcross, CEO of Theriva Biologics, expressed his excitement about the trial's milestones. He remarked, "Reaching our target enrollment not only demonstrates the medical community's interest but also emphasizes the urgent demand for effective therapeutic options against metastatic PDAC. We are looking forward to discussions with regulatory bodies to map out the next steps in the clinical development of VCN-01, especially regarding the possibility of analyzing interim data.”
Understanding Metastatic Pancreatic Cancer
Pancreatic cancer is known for its aggressive nature and is often diagnosed in advanced stages, rendering treatment quite difficult. Most patients end up with either advanced local or metastatic disease, which limits surgical interventions and impacts the effectiveness of standard treatments. Unfortunately, the prognosis is bleak, with only a small percentage of patients eligible for surgical resection when they are diagnosed. The high tendency for the disease to metastasize, often spreading to the liver and other organs, underscores the urgent need for innovative treatments like VCN-01 to enhance survival rates and improve the quality of life for those affected.
Structure and Goals of the VIRAGE Trial
The VIRAGE study is thoughtfully crafted to evaluate the safety and efficacy of VCN-01 in conjunction with standard chemotherapy for patients newly diagnosed with metastatic PDAC. Participants in the trial will receive their chemotherapy every 28 days, while those in the experimental group will get additional doses of VCN-01. Evaluating overall survival and safety will be critical to the trial’s success, along with assessing progression-free survival and response rates—key metrics significant for any future oncology treatments.
Previous Clinical Trials Involving VCN-01
Prior to this trial, VCN-01 had been tested across various cancer types, demonstrating promise in Phase 1 studies that included over 80 participants. Its unique method of both infecting tumor cells and improving chemotherapy delivery highlights the need for continued investigation in future oncology treatment protocols.
About Theriva™ Biologics, Inc.
As a leader in the field of advanced cancer therapeutics, Theriva™ Biologics boasts a comprehensive pipeline aimed at addressing serious unmet medical needs. Their commitment spans both oncolytic virus methods and innovative treatment combinations designed to enhance patient responses across a variety of cancer types. With leading candidates like VCN-01, they strive to create significant improvements in patient care, employing innovative processes that encourage better outcomes.
Frequently Asked Questions
What is the VIRAGE Phase 2b Trial about?
The VIRAGE trial is focused on evaluating the effectiveness of VCN-01 when combined with chemotherapy for patients with metastatic pancreatic cancer, aiming to make significant advancements in treatment.
How does VCN-01 work?
VCN-01 is an oncolytic adenovirus that selectively targets and infects tumor cells, while also breaking down the surrounding stroma to improve treatment effectiveness.
What challenges does pancreatic cancer present?
One of the main challenges with pancreatic cancer is its late diagnosis, which limits surgical options and leads to rapid metastasis; this creates an urgent need for new treatment therapies.
What are the key endpoints of the VIRAGE trial?
The primary endpoints of the trial include assessing the overall survival and safety of VCN-01, along with additional factors like progression-free survival and immune response rates.
What does Theriva Biologics focus on?
Theriva Biologics specializes in developing innovative therapies aimed at addressing high unmet medical needs within oncology, utilizing advanced drug platforms to achieve their goals.
